Amalgamated Bank Sells 720 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Amalgamated Bank trimmed its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 7.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,005 shares of the company’s stock after selling 720 shares during the period. Amalgamated Bank’s holdings in Harmony Biosciences were worth $360,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in HRMY. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Harmony Biosciences by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after purchasing an additional 360 shares in the last quarter. ProShare Advisors LLC boosted its stake in Harmony Biosciences by 7.0% during the first quarter. ProShare Advisors LLC now owns 10,488 shares of the company’s stock worth $352,000 after buying an additional 684 shares in the last quarter. Profund Advisors LLC increased its holdings in Harmony Biosciences by 11.1% in the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock valued at $228,000 after buying an additional 758 shares during the period. CWM LLC raised its stake in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after buying an additional 775 shares in the last quarter. Finally, Summit Global Investments lifted its holdings in shares of Harmony Biosciences by 4.2% during the 2nd quarter. Summit Global Investments now owns 20,164 shares of the company’s stock worth $608,000 after acquiring an additional 807 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Harmony Biosciences stock opened at $33.22 on Monday. The business’s fifty day moving average is $35.98 and its two-hundred day moving average is $33.49. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm has a market cap of $1.89 billion, a P/E ratio of 15.74, a P/E/G ratio of 0.62 and a beta of 0.77. Harmony Biosciences Holdings, Inc. has a 52 week low of $24.70 and a 52 week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS. Equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of analyst reports. UBS Group assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Tuesday, October 29th. Cantor Fitzgerald raised their target price on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Finally, Mizuho upped their price target on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Insider Activity

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 30.80% of the stock is owned by insiders.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.